418 results on '"Deal, Cheri"'
Search Results
2. Author Correction: International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents
3. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement
4. Challenges in the care of individuals with severe primary insulin-like growth factor-I deficiency (SPIGFD): an international, multi-stakeholder perspective
5. Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency: a plain language summary of publication from that of daily somatropin injections to treat children who don't make enough growth hormone to grow adequately. ○ Efficacy refers to how well a drug works in a clinical trial. ○ Children treated with weekly somatrogon had an increased growth rate, similar to that of children treated with daily somatropin. • The safety of weekly somatrogon injections was similar to that of daily somatropin injections. The original scientific article on which this summary is based was published in The Journal of Clinical Endocrinology & Metabolism and can be accessed for free at:https://academic.oup.com/jcem/article/107/7/e2717/6566444. The details of the original article are as follows: Cheri L. Deal, Joel Steelman, Elpis Vlachopapadopoulou, Renata Stawerska, Lawrence A Silverman, Moshe Phillip, Ho-Seong Kim, CheolWoo Ko, Oleg Malievskiy, Jose F. Cara, Carl L. Roland, Carrie Turich Taylor, Srinivas Rao Valluri, Michael P. Wajnrajch, Aleksandra Pastrak, and Bradley S. Miller. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 2022; 107(7): e2717–e2728. The purpose of this plain language summary is to help you to understand the findings from recent research. • Somatrogon is used to treat growth hormone deficiency (the condition under study that is discussed in this summary). Approval varies by country; please check with your local healthcare provider for more details. • The results of this study may differ from those of other studies. Physicians/providers should make treatment decisions based on all available evidence and not on the results of a single study.
6. Gene expression signatures predict response to therapy with growth hormone
7. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement
8. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects
9. Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
10. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: Indications, therapy, and management of adverse effects
11. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations
12. Abnormal Fetal Growth
13. When you are Told That Your Fetus or Newborn has an Endocrine Condition: Perspectives of the Parents
14. Preface
15. Contributors
16. Acknowledgments and Dedication
17. MCDA for the Development of Clinical Practice Guidelines and for the Prioritization Clinical Research Questions
18. Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial
19. Thyroid Function from Birth to Adolescence in Prader-Willi Syndrome
20. A Search for Variables Predicting Cortisol Response to Low-Dose Corticotropin Stimulation Following Supraphysiological Doses of Glucocorticoids
21. Genetic variations at the human growth hormone receptor (GHR) gene locus are associated with idiopathic short stature
22. Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
23. Meier-Gorlin Syndrome
24. Plain language summary for the manuscript: Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency
25. Supplemental data for the manuscript: Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study
26. Isosexual precocious pseudopuberty during mitotane treatment in a child with adrenocortical carcinoma: A case report
27. Are Guidelines for Glucocorticoid Coverage in Adrenal Insufficiency Currently Followed?
28. The Efficacy, Safety, and Pharmacology of a Ghrelin O-Acyltransferase Inhibitor for the Treatment of Prader-Willi Syndrome
29. 21-Hydroxylase epitopes are targeted by CD8 T cells in autoimmune Addison’s disease
30. Intranasal Carbetocin Reduces Hyperphagia and Anxiety and Distress Behaviors in Prader-Willi Syndrome: Results From the CARE-PWS Randomized, Double-Blind, Placebo-Controlled Study
31. Characterization of facial phenotypes of children with congenital hypopituitarism and their parents: A matched case-control study
32. Response to: Does IARS2 Deficiency Cause an Intrinsic Disorder of Bone Development (Skeletal Dysplasia) or Are the Reported Skeletal Changes Secondary to Growth Hormone Deficiency and Neuromuscular Involvement?
33. Retrospective Study of the Potential Benefits and Adverse Events during Growth Hormone Treatment in Children with Prader-Willi Syndrome
34. Mutation in The Nuclear-Encoded Mitochondrial Isoleucyl–tRNA Synthetase IARS2 in Patients with Cataracts, Growth Hormone Deficiency with Short Stature, Partial Sensorineural Deafness, and Peripheral Neuropathy or with Leigh Syndrome
35. Exploring the Association Between DICER1 Mutations and Differentiated Thyroid Carcinoma
36. Role for Tissue-Dependent Methylation Differences in the Expression of FOXE1 in Nontumoral Thyroid Glands
37. Whole-exome sequencing: opportunities in pediatric endocrinology
38. Management of phaeochromocytoma and paraganglioma in patients with germline SDHBpathogenic variants: an international expert Consensus statement
39. Chapter 51 - Abnormal Fetal Growth
40. Switch Data From the Open-Label Extension of the Pivotal Phase 3 Study of Once Weekly Somatrogon Compared to Daily Somatropin in Pediatric Patients With Growth Hormone Deficiency (pGHD)
41. Topline Results of the CARE-PWS Phase 3 Study: Intranasal Carbetocin Improves Hyperphagia and Anxiety and Distress Symptoms in Prader-Willi Syndrome (PWS)
42. Insulin Growth Factor 1 Predicts Central Precocious Puberty in Girls 6 to 8 Years-Old: A Retrospective Study
43. Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained by TPIT Gene Mutations
44. Safety Outcomes During Pediatric GH Therapy: Final Results From the Prospective GeNeSIS Observational Program
45. Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease
46. Insulin-like Growth Factor 1, but Not Insulin-Like Growth Factor-Binding Protein 3, Predicts Central Precocious Puberty in Girls 6–8 Years Old: A Retrospective Study
47. 50 Years Ago in The Journal of Pediatrics: Autoimmune Disorders of Endocrine Glands
48. GH Treatment to Final Height Produces Similar Height Gains in Patients With SHOX Deficiency and Turner Syndrome: Results of a Multicenter Trial
49. Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
50. Abnormal motor cortex excitability is associated with reduced cortical thickness in X monosomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.